MedTrace Logo

A Study of HTD1801 in Healthy Subjects

NCT03099603 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-08-11

No results posted yet for this study

Summary

This is a randomized, double blind, single center, ascending single dose study to evaluate the safety, tolerability, and PK of HTD1801.

Conditions

  • Primary Sclerosing Cholangitis

Interventions

DRUG

HTD1801

A small molecular compound for the treatment of primary sclerosing cholangitis

Sponsors & Collaborators

  • HighTide Therapeutics (Hong Kong) Limited

    lead INDUSTRY

Principal Investigators

  • Janet Wong, Doctor · Nucleus Network Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-03-24
Primary Completion
2017-07-11
Completion
2017-10-03

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03099603 on ClinicalTrials.gov